Optimizing Bridging Therapy Before BCMA-Directed CAR T-Cell Treatment in Relapsed/Refractory Multiple Myeloma: A Real-World Multicenter Analysis
Posted inHematology-Oncology news

Optimizing Bridging Therapy Before BCMA-Directed CAR T-Cell Treatment in Relapsed/Refractory Multiple Myeloma: A Real-World Multicenter Analysis

Bridging therapy before BCMA-directed CAR T-cell infusion in relapsed/refractory multiple myeloma impacts disease control and outcomes. This study analyzes regimen efficacy and safety in 399 patients, highlighting variable responses and safety profiles tied to disease burden and biological risk.
Long-Term Survival Benefit of Daratumumab with Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Insights from the MAIA Final Analysis
Posted inHematology-Oncology news Oncology

Long-Term Survival Benefit of Daratumumab with Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Insights from the MAIA Final Analysis

The MAIA final analysis establishes daratumumab plus lenalidomide/dexamethasone as a superior frontline regimen, significantly extending median overall survival to 7.5 years in transplant-ineligible newly diagnosed multiple myeloma patients.
Targeting Post-Transplant Myeloid Immune Suppression in Multiple Myeloma: Why CSF-1R Blockade May Enhance Lenalidomide Maintenance After ASCT
Posted inClinical Updates Hematology-Oncology news

Targeting Post-Transplant Myeloid Immune Suppression in Multiple Myeloma: Why CSF-1R Blockade May Enhance Lenalidomide Maintenance After ASCT

A new Blood study links relapse after myeloma ASCT to CSF-1R+ immunosuppressive marrow macrophages and shows that CSF-1R inhibition synergizes with lenalidomide in preclinical models, providing a strong translational rationale for post-transplant combination maintenance.